Bristol-Myers Squibb Co. (BMY) PT Raised to $68 at BofA/Merrill Lynch on Increased Confidence of Opdivo/Yervoy Approvability
Tweet Send to a Friend
BofA/Merrill Lynch raised its price target on Bristol-Myers Squibb Co. (NYSE: BMY) to $68.00 (from $64.00) while maintaining a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
